AML Survival After 3 Years Remission – Comparable to General Population
- Hear's a breakdown of the provided text, focusing on the key findings and information presented. It's a summary of a study on long-term outcomes for Acute Myeloid Leukemia...
- * Improved survival: AML survival rates have steadily improved over the decades, with remission rates exceeding 90% when venetoclax is used in initial treatment.
- in essence, the study highlights the progress made in AML treatment, but also underscores the need for further research into the long-term health and well-being of survivors.
Hear’s a breakdown of the provided text, focusing on the key findings and information presented. It’s a summary of a study on long-term outcomes for Acute Myeloid Leukemia (AML) survivors.
Key Takeaways:
* Improved survival: AML survival rates have steadily improved over the decades, with remission rates exceeding 90% when venetoclax is used in initial treatment.
* Increasing Survivor Population: Due to improved survival, the number of AML survivors is expected to continue growing.
* Gaps in Knowledge: Despite these improvements, the long-term needs and potential complications faced by AML survivors are not well understood.
* Study Details:
* Retrospective Analysis: the study analyzed data from 435 AML patients diagnosed between 1991 and 2015 at MD Anderson Cancer Center.
* Remission Duration: Patients included had been in complete remission for at least 36 months.
* Follow-up: The median follow-up period was 7.2 years.
* Median age: Median age at diagnosis was 51 years, and 62 years at relapse.
* Relapse & Mortality:
* Relapse Rate: 11% of patients relapsed after 3 years of remission.
* AML Relapse Death: 9% died due to AML relapse.
* Non-Relapse Death: 10% died from causes other than AML relapse.
* Similar Characteristics: Patients who died from relapse and those who died from non-relapse causes had similar characteristics (age, cytogenetics, common mutations).
* Mutation Findings:
* FLT3-ITD and RAS mutations were common in both relapse and non-relapse death groups.
* Mutations in FLT3,NPM1,IF1,IDH2,and Dnmt3a were more frequent in patients who died in remission compared to those who relapsed.
* Unknown Cause of Death: The cause of death was undetermined for 43% of patients who died from non-relapse causes. Other causes included secondary malignancies, cardiovascular disease, graft-vs-host disease, and infection.
in essence, the study highlights the progress made in AML treatment, but also underscores the need for further research into the long-term health and well-being of survivors. It suggests that while relapse is a concern, non-relapse mortality is also significant, and specific mutations might potentially be associated with different outcomes.